参考文献/References:
[1] Abati E, Bresolin N, Comi G, et al. Advances, challenges, and perspectives in translational stem cell therapy for amyotrophic lateral sclerosis[J]. Mol Neurobiol, 2019, 56(10): 6703-6715.
[2] Oskarsson B, Gendron TF, Staff NP. Amyotrophic lateral sclerosis: an update for 2018[J]. Mayo Clinic Proceedings, 2018, 93(11): 1617-1628.
[3] Mazzini L, Vescovi A, Cantello R, et al. Stem cells therapy for ALS[J]. Expert Opin Biol Ther, 2016, 16(2): 187-199.
[4] Csobonyeiova M, Polak S, Nicodemou A, et al. Induced pluripotent stem cells in modeling and cell-based therapy of amyotrophic lateral sclerosis[J]. J Physiol Pharmacol, 2017, 68(5): 649-657.
[5] Goutman SA, Savelieff MG, Sakowski SA, et al. Stem cell treatments for amyotrophic lateral sclerosis: a critical overview of early phase trials[J]. Expert Opin Investig Drugs, 2019, 28(6): 525-543.
[6] Schultz J. Disease-modifying treatment of amyotrophic lateral sclerosis[J]. Am J Manag Care, 2018, 24(15 Suppl): S327-S335.
[7] Jaiswal MK. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs[J]. Med Res Rev, 2019, 39(2): 733-748.
[8] Yoshino H. Edaravone for the treatment of amyotrophic lateral sclerosis[J]. Expert Rev Neurother, 2019, 19(3): 185-193.
[9] Babu S, Hightower BG, Chan J, et al. Ibudilast(MN-166)in amyotrophic lateral sclerosis- an open label, safety and pharmacodynamic trial[J]. Neuroimage Clin, 2021, 30: 102672.
[10] Trias E, Ibarburu S, Barreto-Núñez R, et al. Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis[J]. J Neuroinflammation, 2016, 13(1): 177.
[11] Bennett CF, Krainer AR, Cleveland DW. Antisense oligonucleotide therapies for neurodegenerative diseases[J]. Annu Rev Neurosci, 2019, 42: 385-406.
[12] Abati E, Bresolin N, Comi G, et al. Silence superoxide dismutase 1(SOD1): a promising therapeutic target for amyotrophic lateral sclerosis(ALS)[J]. Expert Opin Ther Targets, 2020, 24(4): 295-310.
[13] Klim JR, Vance C, Scotter EL. Antisense oligonucleotide therapies for Amyotrophic Lateral Sclerosis: Existing and emerging targets[J]. Int J Biochem Cell Biol, 2019, 110: 149-153.
[14] Silani V, Calzarossa C, Cova L, et al. Stem cells in amyotrophic lateral sclerosis: motor neuron protection or replacement?[J]. CNS Neurol Disord Drug Targets, 2010, 9(3): 314-324.
[15] Tang BL. The use of mesenchymal stem cells(MSCs)for amyotrophic lateral sclerosis(ALS)therapy-a perspective on cell biological mechanisms[J]. Rev Neurosci, 2017, 28(7): 725-738.
[16] 陈璐,樊东升.肌萎缩侧索硬化与肠道菌群相关性的研究进展[J].中华神经科杂志,2021(7):729-733.
[17] Lo Furno D, Mannino G, Giuffrida R. Functional role of mesenchymal stem cells in the treatment of chronic neurodegenerative diseases[J]. J Cell Physiol, 2018, 233(5): 3982-3999.
[18] Bonafede R, Mariotti R. ALS pathogenesis and therapeutic approaches: the role of mesenchymal stem cells and extracellular vesicles[J]. Front Cell Neurosci, 2017, 11: 80.
[19] Thomsen GM, Avalos P, Ma AA, et al. Transplantation of neural progenitor cells expressing glial cell Line-Derived neurotrophic factor into the motor cortex as a strategy to treat amyotrophic lateral sclerosis[J]. Stem Cells, 2018, 36(7): 1122-1131.
[20] Forostyak S, Sykova E. Neuroprotective potential of Cell-Based therapies in ALS: from bench to bedside[J]. Front Neurosci, 2017, 11: 591.
[21] Abdul WS, Law ZK, Ismail N, et al. Cell-based therapies for amyotrophic lateral sclerosis/motor neuron disease[J]. Cochrane Database Syst Rev, 2016, 11(11): CD011742.
[22] Hajivalili M, Pourgholi F, Kafil HS, et al. Mesenchymal stem cells in the treatment of amyotrophic lateral sclerosis[J]. Curr Stem Cell Res Ther, 2016, 11(1): 41-50.
[23] Ahmed LA, Al-Massri KF. Directions for enhancement of the therapeutic efficacy of mesenchymal stem cells in different neurodegenerative and cardiovascular diseases: current status and future perspectives[J]. Curr Stem Cell Res Ther, 2021, 16(7): 858-876.
[24] Bonafede R, Turano E, Scambi I, et al. ASC-Exosomes ameliorate the disease progression in SOD1(G93A)murine model underlining their potential therapeutic use in human ALS[J]. Int J Mol Sci, 2020, 21(10): 3651.
[25] Kook MG, Lee S, Shin N, et al. Repeated intramuscular transplantations of hUCB-MSCs improves motor function and survival in the SOD1 G(93)A mice through activation of AMPK[J]. Sci Rep, 2020, 10(1): 1572.
[26] Barnabe-Heider B, F. Origin of new glial cells in intact and injured adult spinal cord[J]. Cell Stem Cell, 2010, 7(4): 470-482.
[27] Xu LM, Koliatsos VE. Host induction by transplanted neural stem cells in the spinal cord:further evidence for an adult spinal cord neurogenic niche[J]. Regen Med, 2012, 7(6): 785-797.
[28] Tang Y, Le WD. Differential roles of M1 and M2 microglia in neurodegenerative diseases[J]. Mol Neurobiol, 2016, 53(2): 1181-1194.
[29] Liu J, Wang F. Role of neuroinflammation in amyotrophic lateral sclerosis: cellular mechanisms and therapeutic implications[J]. Front Immunol, 2017, 8: 1005.
[30] Noh MY, Lim SM, Oh KW, et al. Mesenchymal stem cells modulate the functional properties of microglia via TGF-β secretion[J]. Stem Cells Transl Med, 2016, 5(11): 1538-1549.
[31] Vercelli A, Mereuta OM, Garbossa D, et al. Human mesenchymal stem cell transplantation extends survival, improves motor performance and decreases neuroinflammation in mouse model of amyotrophic lateral sclerosis[J]. Neurobiol Dis, 2008, 31(3): 395-405.
[32] Zhou, C.Human marrow stromal cells reduce microglial activation to protect motor neurons in a transgenic mouse model of amyotrophic lateral sclerosis[Z],2013:52.
[33] Birger A, Ben-Dor I, Ottolenghi M, et al. Human iPSC-derived astrocytes from ALS patients with mutated C9ORF72 show increased oxidative stress and neurotoxicity[J]. EBioMedicine, 2019, 50: 274-289.
[34] Barbeito L. Astrocyte-based cell therapy: new hope for amyotrophic lateral sclerosis patients?[J]. Stem Cell Res Ther, 2018, 9(1): 241.
[35] Tseng N, Lambie SC, Huynh CQ, et al. Mitochondrial transfer from mesenchymal stem cells improves neuronal metabolism after oxidant injury in vitro: The role of Miro1[J]. J Cereb Blood Flow Metab, 2021, 41(4): 761-770.
[36] Qian K, Huang H, Peterson A, et al. Sporadic ALS astrocytes induce neuronal degeneration in vivo[J]. Stem Cell Reports, 2017, 8(4): 843-855.
[37] Garbuzova-Davis S, Shell R, Mustafa H, et al. Advancing stem cell therapy for repair of damaged lung microvasculature in amyotrophic lateral sclerosis[J]. Cell Transplant, 2020, 29: 963689720913494.
[38] Berry JD, Cudkowicz ME, Windebank AJ, et al. NurOwn, phase 2, randomized, clinical trial in patients with ALS: Safety, clinical, and biomarker results[J]. Neurology, 2019, 93(24): e2294-e2305.
[39] Petrou P, Gothelf Y, Argov Z, et al. Safety and clinical effects of mesenchymal stem cells secreting neurotrophic factor transplantation in patients with amyotrophic lateral sclerosis: results of phase 1/2 and 2a clinical trials[J]. JAMA Neurol, 2016, 73(3): 337-344.
[40] Oh KW, Moon C, Kim HY, et al. Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis[J]. Stem Cells Transl Med, 2015, 4(6): 590-597.
[41] Barczewska M, Maksymowicz S, Zdolińska-Malinowska I, et al. Umbilical cord mesenchymal stem cells in amyotrophic lateral sclerosis: an original study[J]. Stem Cell Rev Rep, 2020, 16(5): 922-932.
[42] Syková E, Rychmach P, Drahorádová I, et al. Transplantation of mesenchymal stromal cells in patients with amyotrophic lateral sclerosis: results of phase I/IIa clinical trial[J]. Cell Transplant, 2017, 26(4): 647-658.
[43] Mazzini L, Gelati M, Profico DC, et al. Human neural stem cell transplantation in ALS: initial results from a phase I trial[J]. J Transl Med, 2015, 13: 17.
[44] Cudkowicz ME, Lindborg SR, Goyal NA, et al. A randomized placebo-controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis[J].Muscle Nerve, 2022,65: 291-302.
[45] Navarro NP, Yeo RW, Brunet A. Aging and rejuvenation of neural stem cells and their niches[J]. Cell Stem Cell, 2020, 27(2): 202-223.
[46] Jeromin A, Bowser R. Biomarkers in neurodegenerative diseases[J]. Adv Neurobiol, 2017, 15: 491-528.
[47] Cappella M, Ciotti C, Cohen-Tannoudji M, et al. Gene therapy for ALS-A perspective[J]. Int J Mol Sci, 2019, 20(18): 4388.
[48] Lee JK, Choi IS, Oh TI, et al. Cell-Surface engineering for advanced cell therapy[J]. Chemistry, 2018, 24(59): 15725-15743.